Actively Recruiting
Evaluating Tislelizumab Plus Chemotherapy in US Minority Patients with Advanced Unresectable or Metastatic Gastric, Gastroesophageal Adenocarcinoma, or Esophageal Squamous Cell Carcinoma
Led by BeOne Medicines · Updated on 2026-10-16
30
Participants Needed
9
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the clinical effects of tislelizumab combined with chemotherapy in US racial and ethnic minority patients who have HER2-negative, PD-L1-positive, locally advanced unresectable or metastatic gastric or gastroesophageal adenocarcinoma GACGEA or esophageal squamous cell carcinoma ESCC. This Phase 2 study aims to assess the pharmacokinetics, activity, and safety of this combination treatment over a period of up to approximately 6 years. Participants will receive tislelizumab given by intravenous infusion at either 200 mg every 3 weeks or 150 mg every 2 weeks, depending on the chemotherapy regimen. The chemotherapy options include FOLFOX oxaliplatin, leucovorin, and 5-fluorouracil, CAPOX oxaliplatin plus oral capecitabine, or cisplatin plus 5-fluorouracil, administered in cycles every 2 or 3 weeks. The study is open-label and non-randomized with two study arms based on the type of cancer. During the study, participants will be monitored for adverse events and serious adverse events for about 12 months. Researchers will also assess tumor response, measure serum levels of tislelizumab, and check for antidrug antibodies. Eligibility assessments include tumor PD-L1 status and organ function tests. The study includes regular visits for treatment administration and safety evaluations, with participants followed for up to six years to gather long-term data.
CONDITIONS
Brief Title
A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States
Research Team
S
Study Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here